Clinical Trials

Phase 1/2 Active not recruiting

88 enrolled

Gastrointestinal

Liver Neoplasms

NCT05286801 2026-03-18

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

86 enrolled

Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05333458 2026-03-18

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Phase 2 Recruiting

27 enrolled

Sarcoma

Sarcoma, Alveolar Soft Part

NCT05411081 2026-03-18

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

200 enrolled

Carcinoma, Renal Cell

NCT04310020 2026-03-17

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

47 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04458922 2026-03-17

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

27 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Phase 2 Recruiting

60 enrolled

Phase 3 Not yet recruiting

Carcinoma, Transitional Cell

NCT07388524 2026-03-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06287775 2026-03-12

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

45 enrolled

DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms

NCT06066138 2026-03-11

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1 Recruiting

30 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT02912559 2026-02-02

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Phase 3 Active not recruiting

712 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast

Breast Neoplasms

NCT05715281 2025-11-25

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

12 enrolled

Other solid neoplasm

Advanced Rare Malignant Solid Neoplasm

NCT02849496 2025-11-24

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Phase 1 Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT03738228 2025-11-12

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Phase 1 Completed

40 enrolled 17 charts

Gynecologic

Uterine Cervical Neoplasms

NCT03228537 2025-11-10

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

28 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02862275 2025-10-23

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Phase 1 Active not recruiting

40 enrolled

Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04729959 2025-10-20

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

59 enrolled

CNS

Astrocytoma, Glioblastoma

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03141684 2025-10-08

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

63 enrolled 1 FDA

Sarcoma

Sarcoma, Alveolar Soft Part

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

51 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04631029 2025-10-03

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Phase 1 Completed

3 enrolled 12 charts

CNS

Brain Neoplasms

NCT02844816 2025-05-22

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Completed

172 enrolled 16 charts